Estrella Immunopharma, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

General form for quarterly reports under Section 13 or 15(d)

Submission of Matters to a Vote of Security Holders

Definitive Proxy Statement

Notification of late filing of Form 10-Q

General form for quarterly reports under Section 13 or 15(d)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Annual report pursuant to Section 13 or 15(d) (amendment)

Annual report pursuant to Section 13 or 15(d)

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Correspondence with the SEC

Amended Initial Registration Statement

Amended Initial Registration Statement

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Entry into a Material Definitive Agreement

Prospectus Supplement for Primary Offering

Registration (IPO) statement under Securities Act of 1933

Other Events

General form for quarterly reports under Section 13 or 15(d)

Other Events

Other Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

General form for quarterly reports under Section 13 or 15(d)

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Other Events

Entry into a Material Definitive Agreement

Other Events

General form for quarterly reports under Section 13 or 15(d)

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

No description available

Other Events

Other Events

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Letter from the SEC

Correspondence with the SEC

Prospectus Supplement for Primary Offering

Other Events

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Entry into a Material Definitive Agreement

Prospectus Supplement for Primary Offering

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Prospectus Supplement for Primary Offering

General form for quarterly reports under Section 13 or 15(d)

Annual report pursuant to Section 13 or 15(d) (amendment)

Prospectus Supplement for Primary Offering

Annual report pursuant to Section 13 or 15(d)

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

General form for quarterly reports under Section 13 or 15(d)

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

General form for quarterly reports under Section 13 or 15(d)

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

General form for quarterly reports under Section 13 or 15(d)

Notification of late filing of Form 10-Q

Correspondence with the SEC

Beneficial ownership report for a holder of more than 5% (Schedule 13D)

Letter from the SEC

General form for quarterly reports under Section 13 or 15(d)

Additional Information for Proxy Statement/ Votes

No description available

Additional Information for Proxy Statement/ Votes

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Definitive Proxy Statement

Correspondence with the SEC

No description available

Preliminary Proxy Statement

General form for quarterly reports under Section 13 or 15(d)

Letter from the SEC

Notification of late filing of Form 10-Q

No description available

Correspondence with the SEC

Annual report pursuant to Section 13 or 15(d)

Letter from the SEC

No description available

Letter from the SEC

Definitive Proxy Statement

No description available

Preliminary Proxy Statement

Liu Cheng

Xu Jiandong

Xu Jiandong

Jia Dengyao

Liu Cheng

Xu Jiandong

Zhang Hong

Wu Xuejun Janelle

Eureka Therapeutics, Inc.

Xu Jiandong

Roberts Marsha

Xu Pei

Wu Fan

Liu Cheng

ALTMAN JEFFREY A

Wen Luqi

Jiang Tao